The impact of tumour histology and recursive partitioning analysis classification on the prognosis of patients treated with whole-brain hypofractionated radiotherapy for brain metastases: analysis of 382 patients

被引:5
|
作者
Buglione, M. [1 ]
Bandera, L. [1 ]
Grisanti, S. [2 ]
Pasinetti, N. [1 ]
Borghetti, P. [1 ]
Barbera, F. [1 ]
Triggiani, L. [1 ]
Costa, L. [1 ]
Shehi, B. [1 ]
Bonetti, B. [1 ]
Magrini, S. [1 ]
机构
[1] Univ Brescia, Dept Radiotherapy, I-25123 Brescia, Italy
[2] Spedali Civil Brescia, Dept Med Oncol, I-25125 Brescia, Italy
来源
RADIOLOGIA MEDICA | 2012年 / 117卷 / 01期
关键词
Brain metastases; Primary histology; Hypofractionated radiotherapy; Recursive partitioning analysis; THERAPY ONCOLOGY GROUP; ANALYSIS RPA CLASSIFICATION; RADIATION-THERAPY; RANDOMIZED-TRIAL; CEREBRAL METASTASES; SINGLE METASTASES; CLINICAL-TRIAL; LUNG-CANCER; IRRADIATION; PALLIATION;
D O I
10.1007/s11547-011-0738-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose. Recursive partitioning analysis (RPA) is a prognostic index capable of predicting survival in patients with brain metastases. Histology of the primary tumour has only recently been introduced among the factors that could potentially affect the prognosis of these patients. The main purpose of this study was to analyse the impact of RPA in correlation with histology of the primary tumour in patients with brain metastases treated with hypofractionated radiotherapy. Materials and methods. A total of 382 patients were treated at the Department of Radiotherapy of Brescia University, and RPA classes were retrospectively assigned to all patients. Univariate and multivariate analyses were then performed to verify the role of the single prognostic variables, for the entire group and for each prognostic class, as well as in correlation with histology of the primary tumour. Results. Most patients were classified as RPA prognostic class 2 (48%). The majority of patients was treated with a total dose of 30 Gy delivered in ten fractions, whereas the dose of 20 Gy in four or five fractions was primarily used in patients classified as RPA class 3. At univariate analysis, the main variable correlating with overall survival (OS) was RPA class (p=0.000). Uni- and multivariate analysis performed on RPA class 1 patients only confirmed the role of general performance status, number of metastases and total radiotherapy dose for predicting OS. In the group with the worst prognosis (RPA class 3), none of the variables had a statistically significant role in improving OS. Tumour histology and radiotherapy dose influence OS, even in RPA class 1 and 2 patients. Conclusions. This analysis confirms that RPA prognostic class is the factor that most predicts survival. Primary tumour histology helps determine prognosis, especially in RPA prognostic classes 1 and 2. As regards RPA class 3, no factor influences survival prognosis.
引用
收藏
页码:133 / 147
页数:15
相关论文
共 50 条
  • [1] The impact of the histology of primary tumor on RPA prognostic classifications in patients (pts) treated for brain metastases (BM) - retrospective analysis of 382 pts treated with hypofractionated whole brain radiotherapy (HWBRT)
    Buglione, M.
    Grisanti, S.
    Lucchini, E.
    Pasinetti, N.
    Goder, A.
    Bonetti, B.
    Costa, L.
    Barbera, F.
    Frata, P.
    Magrini, S. M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 501 - 502
  • [2] The impact of tumour histology and recursive partitioning analysis classification on the prognosis of patients treated with whole-brain hypofractionated radiotherapy for brain metastases: analysis of 382 patientsImpatto dell’istologia e della classificazione RPA nel predire la prognosi di pazienti affetti da metastasi cerebrali e trattati con radioterapia ipofrazionata sull’encefalo in toto: analisi di 382 pazienti
    M. Buglione
    L. Bandera
    S. Grisanti
    N. Pasinetti
    P. Borghetti
    F. Barbera
    L. Triggiani
    L. Costa
    B. Shehi
    B. Bonetti
    S. Magrini
    La radiologia medica, 2012, 117 : 133 - 147
  • [3] Survival in patients with brain metastases treated with whole-brain radiotherapy
    Avila, Jorge
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2018, 22 (03): : 99 - 104
  • [4] Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases
    Rades, Dirk
    Pluemer, Andre
    Veninga, Theo
    Hanssens, Patrick
    Dunst, Juergen
    Schild, Steven E.
    CANCER, 2007, 110 (10) : 2285 - 2292
  • [5] Prognosis of patients treated for intracranial metastases with whole-brain irradiation
    Sundström, JT
    Minn, H
    Lertola, KK
    Nordman, E
    ANNALS OF MEDICINE, 1998, 30 (03) : 296 - 299
  • [6] Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases
    Dziggel, L.
    Segedin, B.
    Podvrsnik, N. H.
    Oblak, I.
    Schild, S. E.
    Rades, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 (05) : 364 - 366
  • [7] Comprehensive Analysis of Blood Test Results Predicting Prognosis in Patients Undergoing Whole-brain Radiotherapy for Brain Metastases
    Nieder, Carsten
    Stanisavljevic, Luka
    Mannsaker, Bard
    ANTICANCER RESEARCH, 2024, 44 (06) : 2637 - 2643
  • [8] Recursive Partitioning Analysis of Systemic Therapy after Radiotherapy in Patients with Brain Metastases
    Nieder, Carsten
    Dalhaug, Astrid
    Haukland, Ellinor
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (03) : 83 - 88
  • [9] Hypofractionated conformal stereotactic radiotherapy alone or in combination with whole-brain radiotherapy in patients with cerebral metastases
    Lindvall, P
    Bergström, P
    Löfroth, PO
    Henriksson, R
    Bergenheim, AT
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (05): : 1460 - 1466
  • [10] Quality of life in patients with brain metastases treated with a palliative course of whole-brain radiotherapy
    Doyle, Megan
    Bradley, Nicole Marie Eve
    Li, Kathy
    Sinclair, Emily
    Lam, Kelvin
    Chan, Grace
    Chow, Edward
    Barnes, Elizabeth A.
    Danjoux, Cyril
    Tsao, May N.
    JOURNAL OF PALLIATIVE MEDICINE, 2007, 10 (02) : 367 - 374